Author

T. Chitlaru

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 7 Approach:experimental assay· 6 Organism:human· 4 Organism:mouse· 3 Assay:proteomics· 3 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

E. Makdasi· 5 shared M. Aftalion· 5 shared R. Alcalay· 5 shared R. Rosenfeld· 5 shared T. Israely· 5 shared A. Mechaly· 4 shared D. Gur· 4 shared E. Epstein· 4 shared

Activity by Year

2020-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

E. Makdasi

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

T cell response following anti COVID-19 BNT162b2 vaccination is maintained against the SARS-CoV-2 Omicron B.1.1.529 variant of concern

H. Cohen, S. Rotem, U. Elia, G. Bilinsky, I. Levy, T. Chitlaru, E. Bar-Haim

The study assesses T cell responses to the ancestral and Omicron SARS-CoV-2 spike proteins post-BNT162b2 vaccination, finding comparable reactivity and a dominant Th1 response.

bioRxiv · Jan 19, 2022Immunology

CRISPR screens for host factors critical for infection by SARS-CoV-2 variants of concern identify GATA6 as a central modulator of ACE2.

M. Israeli, Y. Finkel, Y. Yahalom-Rone, N. Paran, T. Chitlaru, O. Israeli, I. Cohen-Gihon, M. Aftalion, R. Falach, U. Elia, I. Nemet, L. Kliker, M. Mandelboim, A. Beth-Din, T. Israely, , A. Bercovich-Kinori

This study uses CRISPR screens to identify host factors critical for SARS-CoV-2 infection, finding GATA6 as a key modulator of ACE2 expression and viral entry.

bioRxiv · Jul 19, 2021 · PreprintMicrobiology

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants

E. Makdasi, A. Zvi, R. Alcalay, T. Noy-Porat, E. Peretz, A. Mechaly, Y. Levy, E. Epstein, T. Chitlaru, A. Tennenhouse, M. Aftalion, D. Gur, N. Paran, H. Tamir, O. Zimhony, , R. Rosenfeld

This study evaluates the neutralization potency of four SARS-CoV-2 mAbs against spike mutations and two variants of concern, finding that MD65 and BL6 retain effectiveness against B.1.1.7 and B.1.351.

bioRxiv · Apr 1, 2021Immunology

A lipid nanoparticle RBD-hFc mRNA vaccine protects hACE2 transgenic mice against lethal SARS-CoV-2 infection

U. Elia, S. Rotem, E. Bar-Haim, S. Ramishetti, G. S. Naidu, D. Gur, M. Aftalion, M. Israeli, A. Bercovich-Kinori, R. Alcalay, E. Makdasi, T. Chitlaru, R. Rosenfeld, T. Israely, S. Melamed, , O. Cohen

This study evaluates an mRNA vaccine against SARS-CoV-2 in hACE2 transgenic mice, showing 70% protection against a lethal infection.

bioRxiv · Mar 29, 2021Microbiology

Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice

T. Noy-Porat, A. Mechaly, Y. Levy, E. Makdasi, R. Alcalay, D. Gur, M. Aftalion, R. Falach, S. Leviatan Ben-Arye, S. Lazar, A. Zauberman, E. Epstein, T. Chitlaru, S. Weiss, H. Achdout, , R. Rosenfeld

This study identifies and characterizes neutralizing antibodies targeting the SARS-CoV-2 spike N-terminal domain, showing their protective efficacy in mice.

bioRxiv · Feb 2, 2021Immunology

Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody

R. Rosenfeld, T. Noy-Porat, A. Mechaly, E. Makdasi, Y. Levy, R. Alcalay, R. Falach, M. Aftalion, E. Epstein, D. Gur, T. Chitlaru, E. B. Vitner, S. Melamed, B. Politi, A. Zauberman, , O. Mazor

This study shows that the human monoclonal antibody MD65 can rescue 100% of SARS-CoV-2 infected mice when administered up to 3 days post-exposure.

bioRxiv · Oct 26, 2020Immunology

Tiger team: a panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

T. Noy-Porat, E. Makdasi, R. Alcalay, A. Mechaly, Y. Levy, A. Bercovich-Kinori, A. Zauberman, H. Tamir, Y. Yahalom-Ronen, M. Israeli, E. Epstein, H. Achdout, S. Melamed, T. Chitlaru, S. Weiss, , R. Rosenfeld

This paper isolates and characterizes a panel of human neutralizing monoclonal antibodies targeting SARS-CoV-2 spike at multiple epitopes, suggesting their potential for combined post-exposure therapy.

bioRxiv · May 20, 2020Immunology